Scholarlink

<p>Breast cancer stands as the most prevalent type of cancer globally and the leading cause of cancer-related deaths among women. Owing to the substantial side effects associated with conventional treatments such as chemotherapy and radiotherapy, drug delivery systems have been proposed to co-deliver drugs with varying physicochemical properties to tumor cells, thereby achieving a synergistic therapeutic effect. Herein, we designed novel liposomes by membrane hydration method to co-deliver crocetin (CRO) and the chemotherapeutic drug docetaxel (DTX) for the treatment of breast cancer in order to potentiate the efficacy of chemotherapy. The prepared DTX-CRO liposomes (DTX-CRO-Lip) were characterized by transmission electron microscopy (TEM) and dynamic light scattering analysis. DTX-CRO-Lip showed homogeneous spherical morphology and the mean particle size of 75.35 ± 0.52&#xa0;nm, polydispersity index of 0.26 ± 0.01, and zeta potential of -0.16 ± 0.19&#xa0;mV. The in vitro drug release study and MTT assays showed that DTX-CRO-Lip had sustained drug release effects and synergistic antitumor effect. The in vivo antitumor efficacy was verified on 4T1 tumor-bearing mice. DTX-CRO-Lip showed the best antitumor efficacy and no apparent side effects, suggesting that it is a promising drug delivery system for the synergistic treatment of breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Docetaxel and crocetin co-loaded liposomes for synergistic breast cancer therapy

  • 期刊论文

  • 发表日期：

    2026年1月27日

查看全文
  • Qingqing Li,
  • Yufeng Liu,
  • Tianyu Zhu,
  • Defeng Xu,
  • Hang Hu

摘要

Breast cancer stands as the most prevalent type of cancer globally and the leading cause of cancer-related deaths among women. Owing to the substantial side effects associated with conventional treatments such as chemotherapy and radiotherapy, drug delivery systems have been proposed to co-deliver drugs with varying physicochemical properties to tumor cells, thereby achieving a synergistic therapeutic effect. Herein, we designed novel liposomes by membrane hydration method to co-deliver crocetin (CRO) and the chemotherapeutic drug docetaxel (DTX) for the treatment of breast cancer in order to potentiate the efficacy of chemotherapy. The prepared DTX-CRO liposomes (DTX-CRO-Lip) were characterized by transmission electron microscopy (TEM) and dynamic light scattering analysis. DTX-CRO-Lip showed homogeneous spherical morphology and the mean particle size of 75.35 ± 0.52 nm, polydispersity index of 0.26 ± 0.01, and zeta potential of -0.16 ± 0.19 mV. The in vitro drug release study and MTT assays showed that DTX-CRO-Lip had sustained drug release effects and synergistic antitumor effect. The in vivo antitumor efficacy was verified on 4T1 tumor-bearing mice. DTX-CRO-Lip showed the best antitumor efficacy and no apparent side effects, suggesting that it is a promising drug delivery system for the synergistic treatment of breast cancer.